Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients With Castration-resistant Prostate Cancer

NCT01020305 is registered in ClinicalTrials.gov with Sandy Srinivas as lead sponsor.

NCT NCT01020305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01020305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients With Castration-resistant Prostate Cancer
Lead sponsor
Sandy Srinivas
Phase
Phase 1/2
Overall status
Terminated
Start date
October 31, 2009
Completion date
April 30, 2012
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

androgen-insensitive prostate cancer, castrate-resistant prostate cancer (crpc), hormone-refractory prostate cancer, metastatic disease, prostate cancer, prostatic neoplasms